Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: Outcome of study participants at 1-year adjusted age

Pediatrics

Volumn 104, Issue 1 I, 1999, Pages 15-21

  O'Shea, T Michael ^a   Kothadia, Jamanadas M ^a   Klinepeter, Kurt L ^a   Goldstein, Donald J ^a   Jackson, Barbara G ^a   Weaver III, R Grey ^a   Dillard, Robert G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchopulmonary dysplasia; Cerebral palsy; Chronic lung disease; Developmental outcome; Dexamethasone; Randomized controlled trials; Very low birth weight

Indexed keywords

DEXAMETHASONE; PLACEBO;

ARTICLE; ASSISTED VENTILATION; CEREBRAL PALSY; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VERY LOW BIRTH WEIGHT;

CEREBRAL PALSY; CHILD DEVELOPMENT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE; NORTH CAROLINA; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; STATISTICS, NONPARAMETRIC; VENTILATOR WEANING;

EID: 0033011082     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.104.1.15     Document Type: Article

References (48)

1. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985;75:106-111
2. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989;320:1505-1510
3. Harkavy KL, Scanlon JW, Chowdhry PK, Grylack LJ. Dexamethasone therapy for chronic lung disease in ventilator-and oxygen-dependent infants: a controlled trial. J Pediatr. 1989;115:979-983
4. Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics. 1990;86:722-727
5. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics. 1991;88:421-427
6. Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease. Acta Paediatr. 1992;81:751-756
7. Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics. 1995;95: 584-590
8. Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr. 1990;117: 273-282
9. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics. 1996;98:204-210
10. Brozanski BS, Jones JG, Gilmour CH, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr. 1995;126:769-776
11. Yeh TF, Lin YJ, Hsieh WS, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics 1997;100(4). URL: http://www.pediatrics.org/cgi/content/full/100/ 4/e3
12. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BW, Dillard RG. Follow-up of preterm infants treated with dexamethasone for chronic lung disease. Am J Dis Child. 1993;147:658-661
13. Furman L, Hacl M, Watts C, Borawski-Clark E, Baley J, Hook B. Twenty-month outcome in ventilator dependent, very low birth weight infants born during the early years of dexamethasone therapy. J Pediatr. 1995;126:434-440
14. Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics. 1995;96:897-906
15. Yeh TF, Lin YJ, Huang CC, Chen YJ, Tsai WF, Lien YJ. Early postnatal (<12 hrs) dexamethasone therapy for prevention of BPD in preterm infants with RDS - a two-year follow-up study. Pediatrics. 1998;101(5). URL: http://www.pediatrics.org/cgi/content/full/101/5/e7
16. Committee on An International Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Pediatrics. 1984;74:127-133
17. O'Shea TM, Klinepeter KL, Goldstein DJ, Jackson BW, Dillard RG. Survival and developmental disability in infants with birth weight 501-800 grams, born between 1979 and 1994. Pediatrics. 1997;90:982-986
18. Bayley N. The Bayley Scales of Infant Development. New York, NY: Psychological Corporation; 1969
19. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service, Inc; 1984
20. Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corporation; 1993
21. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82:527-532
22. Hyde I, English RE, Williams JD. The changing pattern of chronic lung disease of prematurity. Arch Dis Child. 1989;64:448-451
23. Heneghan MA, Sosulski R, Baquero JM. Persistent pulmonary abnormalities in newborns: the changing picture of bronchopulmonary dysplasia. Pediatr Radiol. 1986;16:180-184
24. Lubchenco LO, Hansman C, Boyd E. Intrauterine growth as estimated from Ii vebom birth-weight data at 24 to 42 weeks of gestation. Pediatrics. 1963;37:403-408
25. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard Score, expanded to include extremely premature infants. J Pediatr. 1991;119:417-423
26. Stewart AL, Reynolds EOR, Hope PL, et al. Probability of neurodevelopmental disorders estimated from ultrasound appearance of brains of very preterm infants. Dev Med Child Neurol. 1987;29:3-11
27. Leviton A, Paneth N. White matter damage in preterm newborns - an epidemiologic perspective. Early Hum Dev. 1990;24:1-22
28. O'Shea TM, Volberg F, Dillard RG. Reliability of interpretations of cranial ultrasounds made on very low birth weight neonates. Dev Med Child Neural. 1993;35:97-101
29. Saigal S, Rosenbaum P, Hattersley B, Milner R. Decreased disability rate among 3-year survivors weighing 501 to 1000 grams at birth and born to residents of a geographically defined region from 1981 to 1984 compared with 1977 to 1980. J Pediatr. 1989;114:839-846
30. Roth SC, Baudin J, Pezzani-Goldsmith M, Townsend J, Reynolds EOR, Stewart AL. Relation between neurodevelopmental status of very preterm infants at one and eight years. Dev Med Child Neurol. 1994;36: 1049-1062
31. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley and Sons; 1981
32. PC-SAS, Cary, NC: SAS Institute
33. STATXACT, Cambridge, MA: Cytel
34. Batton DG, Roberts C, Trese M, Maisels MJ. Severe retinopathy of prematurity and steroid exposure. Pediatrics. 1992;90:534-536
35. Ramanathan R, Siassi B, deLemos RA. Severe retinopathy of prematurity in extremely low birth weight infants after short-term dexamethasone therapy. J Perinatol 1995;15:178-182
36. Shinwell ES, Karplus M, Zmora E, et al. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Arch Dis Child. 1996;74:F33-F37
37. Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatr Res. 1994;36: 122-128
38. Brownlee KG, Ng PC, Henderson MJ, Smith M, Green JH, Dear PRF. Catabolic effect of dexamethasone in the preterm baby. Arch Dis Child. 1992;67:1-4
39. Gibson AT, Pearse RG, Wales JKH. Growth retardation after dexamethasone administration: assessment by knemometry. Arch Dis Child. 1993; 69:505-509
40. Van Goudoever JB, Wattimena JDL, Carnielli VP, Sulkers EJ, Degenhart HJ, Sauer PJJ. Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia. J Pediatr. 1994;124:112-118
41. Benesova O, Pavlik A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology. 1989;28:89-97
42. Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998;338:1112-1118
43. Noble-Jamieson CM, Regev R, Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. Eur J Pediatr. 1989;148:365-367
44. Jarvis S, Hey E. Measuring disability and handicap to cerebral palsy. In: Stanley F, Alberman E, eds. The Epidemiology of Cerebral Palsies. Philadelphia, PA: JB Lippincott Co; 1984;41-42
45. Paneth N, Rudelli R, Kazam E, Monte W. Prognosis. In: Brain Damage in the Preterm Infant. London, UK: MacKeith Press; 1994:171-185
46. Nelson KB, Ellenberg JH. Children who "outgrew" cerebral palsy. Pediatrics. 1982;69:529-536
47. Stanely FJ. Using cerebral palsy data in the evaluation of neonatal intensive care: a warning. Dev Med Child Neurol. 1982;24:93-94
48. Hamill PW, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr. 1979;32:607-629